Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?

References

• Coiffier B, Lepage E, Brière J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, . Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, . Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824–4831.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, . Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27: 1607–1614.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–2466.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-López AJ, Bodkin DJ, . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266–3274.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MH, . The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Itälä M, Geisler CH, Kimby E, . Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69: 129–134.
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, . Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98: 1326–1331.
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-López AJ, . Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655–661.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, . Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, . Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4070–4078.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, . Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506–1514.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010;7:521–532.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, . Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319–2325.
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Löffler H, . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.Lancet 1996;347:1432–1438.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885–891.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, . Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-López AJ, White CA, . Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Hainsworth JD, Burris HA III, Morrissey LH, . Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052–3056.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, . Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746–1751.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Giles FJ, . Single-agent rituximab in early-stage chronic lymphocytic leukemia (CLL). Blood 2001;98(Suppl. 1): Abstract 1533.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Secreto CR, Knox TR, . Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010;115:1755–1764.
   PubMed Web of Science ®Google Scholar
• Manshouri T, Do KA, Wang X, . Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507–2513.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, . Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191–5201.
   PubMed Web of Science ®Google Scholar
• Almasri NM, Duque RE, Iturraspe J, . Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259–263.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, . CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383–3389.
   PubMed Web of Science ®Google Scholar
• Tam CS, Otero-Palacios J, Abruzzo LV, . Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008;141:36–40.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Lerner S, . The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931–1939.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Li J, Zhi J, Wenger M, . Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 2012 Mar 9. [Epub ahead of print]
   Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112: 975–980.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, . Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117: 3016–3024.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, . Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, . Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412–2420.
   PubMed Web of Science ®Google Scholar
• Nikitin A, Stadnik A, Salogub N, . Retrospective comparison of efficacy and toxicity of FC and FCR regimens in untreated patients with B-cell chronic lymphocytic leukemia. Haematologica 2008;93(Suppl. 1): Abstract 0095.
   Google Scholar
• Smolej L, Lysak D, Papjik T, . Fludarabine, cyclophosphamide and rituximab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): Retrospective analysis of Czech CLL Study Group. Haematologica 2009;94(Suppl. 2): Abstract 0927.
   Google Scholar
• Kay NE, Geyer SM, Call TG, . Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, . Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79: 107–113.
   PubMed Web of Science ®Google Scholar
• Reynolds C, Di Bella N, Lyons RM, . Phase III Trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012;30:1232–1240.
   Google Scholar
• Foon KA, Boyiadzis M, Land SR, . Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498–503.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Wierda WG, Faderl S, . FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood 2005;106(Suppl. 1): Abstract 2117.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Jurcic JG, Noy A, . Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patietns with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009;27: 491–497.
   PubMed Web of Science ®Google Scholar
• Weiss MA, Glenn M, Maslak P, . Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000;14: 1577–1582.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, . Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33–43.
   PubMed Web of Science ®Google Scholar